This webcast is not certified for contact hours.

Release Date: May 11, 2019
Expiration Date: May 10, 2020

Overview

Given the important and ever-increasing role of nurses in the care and management of patients with ovarian cancer, it is critical for oncology nurses to understand the effectiveness of novel PARP inhibitor therapies, strategies to mitigate and manage adverse events (AEs), and the significance of counseling their patients concerning the use of these approaches. This webcast will provide expert interpretation of emerging data and guidance regarding the use of PARP inhibitors, as well as dosing, AE management strategies, and patient perspectives.

Target Audience

The target audience for this activity is oncology nurses, nurse practitioners, and other clinicians who treat patients with ovarian cancer.  

Learning Objectives

After completing this activity, participants should be able to:

• Identify patients with ovarian cancer who are most appropriate to receive treatment with PARP inhibitors
• Evaluate recent clinical updates and novel indications of PARP inhibitors for the treatment of patients with ovarian cancer
• Discuss approaches for PARP inhibitors that incorporate patient perspectives regarding maintenance therapy
• Assess nursing interventions and treatment management strategies to prevent and mitigate therapeutic-related adverse events, including the utilization of dose modification guidelines

Presentations

Patient Selection for PARP Inhibitor Therapy: Aligning Patients With the Proper Therapy
Paula J. Anastasia, RN, MN, AOCN

What Do the Clinical Data Tell Us Regarding PARP Inhibitors
Kathleen Moore, MD

Managing Patients Receiving PARP Inhibitors
Kimberly Halla, MSN, FNP-C

Deciding to Stay on Maintenance Therapy: A Patient’s Perspective

Method of Participation

There are no fees for viewing this activity. 

Provider

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) (provider) and Bio Ascend LLC.

Disclosure Statement

All planners and faculty participating in continuing education activities provided by the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis. 

The following speakers and planning committee members listed below have stated they have no financial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity.

• Paula Anastasia, RN, MN, AOCN

• Kelly Chase, MA

• Dru S. Dace, PhD

• Kimberly Halla, MSN, FNP-C

• Heidi Keeler, PhD, RN

• Renee Paulin, MSN, RN, CWOCN

• Kraig Steubing, BS

• Judy – Patient Presenter

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information they planned and/or present is done so fairly and without bias: 

Kathleen Moore, MD states that she has received honoraria for advisory board participation from the following companies: AstraZeneca, Clovis, Immunogen, Merck, Pfizer, Genentech/Roche, Aravive, OncoMed, VBL Therapeutics, Tesaro, and Janssen. Dr. Moore served as an international PI for SOLO-1 and national PI for QUADRA and ARIEL (all PARPi studies).

Stefanie Solomon, JD states that she is a consultant for Deciphera Pharmaceuticals and Moderna Pharmaceuticals.

The following speaker(s) plan to discuss off-label uses for the following product/drug:

• Dr. Kathleen Moore: olaparib, veliparib, talazoparib, rucaparib, niraparib: clinical trial utilization

Non-Endorsement of Products

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

Support

The UNMC College of Nursing CNE Program and Bio Ascend thank the following companies for their generous support of this program in the form of educational grants: AstraZeneca and Tesaro, Inc.

Technical Requirements

This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.